Charles Schwab
SION icon

Charles Schwab’s Sionna Therapeutics SION Stock Holding History

Charles Schwab’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.71M Buy
129,753
+9,500
+8% +$380K ﹤0.01% 2415
2026
Q1 		$4.82M Sell
120,253
-3,433
-3% -$131K ﹤0.01% 2418
2025
Q4 		$5.09M Buy
123,686
+12,190
+11% +$462K ﹤0.01% 2448
2025
Q3 		$3.28M Buy
111,496
+18,664
+20% +$406K ﹤0.01% 2604
2025
Q2 		$1.61M Buy
92,832
+28,188
+44% +$369K ﹤0.01% 2738
2025
Q1 		$676K Buy
+64,644
New +$1.06M ﹤0.01% 2975

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Charles Schwab's SION Position: Q2 2026 in Review

Charles Schwab increased its Sionna Therapeutics (SION) stake by 7.9% in Q2 2026, buying an estimated $380K and bringing the position to 129,753 shares worth $5.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2415.

Charles Schwab first reported a position in SION in Q1 2025 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Charles Schwab held 129,753 shares of Sionna Therapeutics worth $5.71M as of Q2 2026.
  • Charles Schwab bought 9,500 Sionna Therapeutics shares in Q2 2026, an estimated $380K.
  • Sionna Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2415 holding.
  • Charles Schwab first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.